A tumor often creates barriers or bottlenecks not to proliferate but to evade immune detection and control.
At Larkspur, we couple insights into the chemistry of the tumor with LarkX, our proprietary machine-learning-enabled gene signature platform, to unlock previously intractable targets shared by both the tumor and the immune system.
LarkX bioinformatics approach focuses treatment on likely responders resulting in smaller, more targeted trials that drive rapid proof of concept and enable expansion into indications enriched for responders.